Azoospermia, defined as the complete absence of spermatozoa in the ejaculate, represents a significant cause of male infertility. It affects approximately 1% of the general male population and up to 10–15% of infertile men. Azoospermia is broadly classified into obstructive and non-obstructive forms, each with distinct etiologies, diagnostic pathways, and management strategies.
Obstructive azoospermia occurs when sperm production within the testes is preserved but blocked along the reproductive tract. Causes include vas deferens obstruction, prior vasectomy, infections leading to scarring, and congenital absence of the vas deferens. In contrast, non-obstructive azoospermia arises from impaired spermatogenesis due to primary testicular failure, genetic abnormalities, hormonal deficiencies, or exposure to gonadotoxic agents.
The diagnostic workup begins with repeated semen analyses to confirm the absence of sperm. Hormonal profiling—including follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone—helps differentiate testicular failure from obstruction. Elevated FSH levels typically suggest primary testicular dysfunction. Scrotal ultrasonography and transrectal ultrasound may identify structural anomalies, while genetic testing is recommended in severe cases.
Therapeutic options depend on etiology. Microsurgical sperm retrieval techniques combined with intracytoplasmic sperm erotic injection (ICSI) have revolutionized fertility prospects. Hormonal therapy may benefit selected patients with hypogonadotropic hypogonadism. A structured, individualized approach is essential for optimal outcomes.
Leave a Reply